Mao Mu

Mao Mu

Auto-generated profile, based on publicly available information

Mao Mu

Department of Infection, Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2018 in Food & Function
Verified
Journal Article
Open access
PDF file
JZJuanjuan Zhu
Juanjuan Zhu
MZMingyu Zhou
Mingyu Zhou
XZXueke Zhao
Xueke Zhao
MMMao Mu
Mao Mu
MCMingliang Cheng
Mingliang Cheng
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent diseases worldwide. Blueberry, combined with probiotics (BP), might be a potential candidate for NAFLD treatment, due to its anti-inflammatory and anti-apoptotic properties. Here, we investigated whether the anti-inflammatory cytokine, IL-22, was involved in the therapeutic process of BP, using cell and rat models of NAFLD. Results indicated that BP significantly reduced lipid droplets and triglyceride (TG) accumulation in NAFLD cells. However, when IL-22 was deficient, the lipid droplets and TG content were significantly increased. In vivo, the serum parameters and pathological degree of NAFLD rats were significantly improved by BP, while IL-22 silencing significantly abolished the BP effect. Immunohistochemistry, immunofluorescence, qRT-PCR, and western blotting showed that the NAFLD group expressed significantly lower levels of IL-22, JAK1, and STAT3, and higher levels of BAX, than the normal group. Furthermore, BP significantly elevated the levels of IL-22, JAK1 and STAT3, and reduced the level of BAX in NAFLD, while IL-22 silencing prevented BP from restoring the expression of JAK1, STAT3, and BAX. We conclude that IL-22 is vital for the therapeutic effect of BP, and acts via activation of JAK1/STAT3 signaling and inhibition of the apoptosis factor BAX, which makes IL-22 a promising target for therapy of NAFLD.

1 April 2010
Verified
Journal Article
Closed access
YWYu-Ping Wang
Yu-Ping Wang
MCMingliang Cheng
Mingliang Cheng
BZBao-Fang Zhang
Bao-Fang Zhang
MMMao Mu
Mao Mu
MZMing-Yu Zhou
Ming-Yu Zhou
CLCheng-Xiu Li
Cheng-Xiu Li

9 November 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
LYLei Yu
Lei Yu
BZBao-Fang Zhang
Bao-Fang Zhang
MCMing-Liang Cheng
Ming-Liang Cheng
XZXue-Ke Zhao
Xue-Ke Zhao
QZQuan Zhang
Quan Zhang
WLWang-Sheng Li
Wang-Sheng Li
// Lei Yu 1, 2, * , Bao-fang Zhang 3, * , Ming-liang Cheng 2 , Xue-ke Zhao 2 , Quan Zhang 2 , Ya-xin Hu 2 , Hua-juan Liu 2 , Mao Mu 2 , Bi Wang 2, 4 , Guo-zhen Yang 2 , Li-li Zhu 2 , Shuai Zhang 5 , Yu-mei Yao 2 , Yi-ju Cheng 2 , Wang-sheng Li 6 1 The First Affiliated Hospital of Jinan University, Guangdong 510632, Guangzhou, China 2 The Affiliated Hospital, Guizhou Medical University, Guiyang 550004, Guizhou, China 3 The First Affiliated Hospital, Soochow University, Suzhou 215006, Jiangsu, China 4 Department of Eugenics and Genetics, Guiyang Maternal and Child Health-Care Hospital, Guiyang 550003, Guizhou, China 5 Department of Interventional Radiology, Cancer Hospital of Guizhou Medical University, Guiyang 550004, Guizhou, China 6 Department of Clinical Laboratory, Liupanshui People’s Hospital, Liupanshui 553401, Guizhou, China * These authors contributed equally to this work and should be considered as co-first authors Correspondence to: Ming-liang Cheng, e-mail: gmcmingliang_cheng@163.com Guo-zhen Yang, e-mail: gmcguozhen_yang@163.com Keywords: hepatitis B virus, hepatocellular carcinoma, liver cirrhosis, mutation, risk Received: February 29, 2016 Accepted: April 28, 2016 Published: May 17, 2016 ABSTRACT The long-term outcomes of liver cirrhosis (LC) and hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection are associated with specific HBV genotypes and mutations in the virus genome. However, a number of gene-disease association studies have yielded inconsistent results in the field. To investigate this inconsistency, we conducted a meta-analysis from 118 studies involving a total of 9,418 HCC cases, 2,697 LC cases, and 18,785 HBV-infected participants for 11 mutations of HBV to evaluate the epidemiological evidence of the relationship. Overall, 10 mutants (Pre-S mutation, A1762T/G1764A double mutations, G1896A, G1899A, T1753V, C1653T, G1766A, A1762T, G1764A, T1768A) were significantly associated with increased HCC risk with odds ratio (OR) range from 1.80 to 4.27, while no associations were found for C1858T. We found a significant dose–risk relationship between the number of mutations in HBV genome and HCC, in which high risks for HCC were associated with mutation numbers more than 5 (OR = 18.45, 95% CI: 7.86–43.29). By pooling 15 prospective studies, A1762T/G1764A, Pre-S, T1753V, and C1653T mutation was identified as good predictor of HCC risk, showing ORs from 1.73 to 4.54. In addition, significantly elevated LC risks were associated with 6 mutants (A1762T/G1764A double mutations, G1896A, G1899A, T1753V, C1653T, Pre-S mutation), with OR range from 1.76 to 4.10. Our results suggested that HBV mutations alone or in combination may be of clinical significance for predicting hepatocarcinogenesis.

1 January 2009 in World Chinese Journal of Digestology
Verified
Journal Article
Open access
QZQuan Zhang
Quan Zhang
MCMingliang Cheng
Mingliang Cheng
QLQin Liu
Qin Liu
MMMao Mu
Mao Mu
YZYing-Ying Zhang
Ying-Ying Zhang
BLBi-Yun Liu
Bi-Yun Liu

1 June 2010
Verified
Journal Article
Closed access
SLSan-Du Liu
San-Du Liu
MCMingliang Cheng
Mingliang Cheng
JJJi-Dong Jia
Ji-Dong Jia
KDKai-Sheng Deng
Kai-Sheng Deng
JYJing Yang
Jing Yang
MMMao Mu
Mao Mu

1 April 2014
Verified
Journal Article
Closed access
SLSandu Liu
Sandu Liu
MCMingliang Cheng
Mingliang Cheng
MMMao Mu
Mao Mu
QYQingkun Yang
Qingkun Yang
To investigate the clinical features and rate of natural viral clearance in patients with hepatitis C virus (HCV) infection acquired by blood transfusion from a single donor. Ninety-six patients who acquired HCV infection between January 1998 and December 2002, upon receipt of donated blood from a single infected individual in Guizhou,were included in this retrospective cross-sectional study. Patients were clinically assessed to determine levels of anti-HCV antibodies, HCV RNA and biochemical indicators of liver function,as well as features of liver structure (by abdominal B ultrasonography and elastography). HCV genetic testing was used to determine the virus genotype. Measurement data were expressed as mean ± standard deviation. Count data were analyzed by the x² test,with P less than 0.05 indicating statistical significance. All 96 patients tested positive for antiHCV antibodies. The majority of patients (70%; 34:33 male:female) had HCV RNA more than or equal to 1.0 * 103 copies/ml. All patients carried the same HCV genotype as the single blood donor:genotype lb. The overall rate of natural HCV clearance was 30.2%. but males had a significantly lower rate (19.0% (8/42) vs. females:38.9% (21/54);x²=4.41,P=0.023) as did older patients (more than 40 years-old:16.1% (5/31) vs .less than or equal to 40 years-old:36.9% (24/65);x²=4.30,P=0.028). The overall rate of chronic HCV infection (CHC) was 69.8%,but the rate was significantly lower in younger patients (less than or equal to 40 years-old:63.1% (41/65) vs. more than 40 years-old:83.9% (26/31);x²=6.67,P=0.028). Among the 67 patients with CHC,12 had symptoms of mild weakness,anorexia and abdominal distention,11 had elevated serum alanine aminotransferase (116.25 +/- 24.65 U/L) and stage 3 or 4 fibrosis (liver elasticity values more than or equal to 5.1 kPa),and three had mildly abnormal serum bilirubin (32.56 ± 5.28 mumol/L). Fifteen patients showed signs of chronic hepatitis and one patient showed signs of cirrhosis by abdominal B ultrasonography. None of the patients showed signs of hepatocellular carcinoma. The course of blood transfusion acquired HCV infection is largely unknown and natural viral clearance rate may be associated with sex-and age-related factors.